.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
McKesson
Novartis
US Department of Justice
Cantor Fitzgerald
Daiichi Sankyo
Medtronic
Accenture
Express Scripts
Federal Trade Commission

Generated: June 28, 2017

DrugPatentWatch Database Preview

NUVIGIL Drug Profile

« Back to Dashboard

What is the patent landscape for Nuvigil, and what generic Nuvigil alternatives are available?

Nuvigil is a drug marketed by Cephalon and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NUVIGIL is armodafinil. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the armodafinil profile page.

Summary for Tradename: NUVIGIL

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list9
Bulk Api Vendors: see list15
Clinical Trials: see list12
Patent Applications: see list2,509
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NUVIGIL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-001Jun 15, 2007ABRXYesNo7,132,570*PED► SubscribeY► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-005Mar 26, 2009ABRXYesNo7,132,570*PED► SubscribeY► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-002Mar 26, 2009DISCNYesNo7,297,346*PED► SubscribeY► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-005Mar 26, 2009ABRXYesNo7,297,346*PED► SubscribeY► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-001Jun 15, 2007ABRXYesNo7,297,346*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NUVIGIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-005Mar 26, 2009RE37516*PED► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-002Mar 26, 2009RE37516*PED► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-001Jun 15, 20074,927,855*PED► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-004Jun 15, 20074,927,855*PED► Subscribe
Cephalon
NUVIGIL
armodafinil
TABLET;ORAL021875-005Mar 26, 20094,927,855*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NUVIGIL

Drugname Dosage Strength RLD Submissiondate
armodafinilTablets100 mg and 200 mgNuvigil9/11/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Express Scripts
Chinese Patent Office
Merck
Farmers Insurance
Accenture
McKinsey
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot